# US 2013/0274193 A1 · Tfpi inhibitors and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274193 A1
- Document ID: US20130274193A1
- Status: Published application
- Kind: A1
- Application number: 13/827,160
- Filed: 2013-03-14
- Published: 2013-10-17
- Earliest claimed: 2008-12-19
- Assignees: Baxter Healthcare S.A.; Baxter International Inc.
- Inventors: Michael Dockal; Hartmut Ehrlich; Friedrich Scheiflinger; Ulf Reimer; Ulrich Reineke; Thomas Polakowski; Eberhard Schneider
- Web page: https://patentgrep.com/patent/US20130274193A1

## CPC

- C07K 14/4703: {Inhibitors; Suppressors}
- A61K 47/551: {one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid}
- A61K 47/557: {the modifying agent being biotin}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/001: {by chemical synthesis}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.

## Claims

### Claim at position 1

-32. (canceled)

### Claim 33

A peptide that binds TFPI, comprising the following structure of formula V:
X2001-X2002-X2003-X2004-X2005-X2006-[X2007-X2008-X2009-X2010-X2011-X2012-X2013-X2014-X2015-X2016-X2017-X2018]-X2019-X2020-X2021-X2022-X2023 (V) (SEQ ID NO: 3118)
wherein X2001 is either present or absent, whereby in case X2001 is present it is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W;
wherein X2002 is either present or absent, whereby in case X2002 is present it is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W;
wherein X2003 is an amino acid selected from the group consisting of A, F, I, K, L, R, S, T, V, W and Y;
wherein X2004 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V and W;
wherein X2005 is W;
wherein X2006 is an amino acid selected from the group consisting of F, H, I, K, L, R, V and W;
wherein X2007 is an amino acid selected from the group consisting of C, Hcy, Dap and K, preferably selected from the group consisting of C and Hcy;
wherein X2008 is an amino acid selected from the group consisting of A, G, R, S and T;
wherein X2009 is an amino acid selected from the group consisting of a, A, I, K, L, M, m, Nle, p, R, Sem and V;
wherein X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P, R, S, T and V;
wherein X2011 is an amino acid selected from the group consisting of D, E, G, S, and T;
wherein X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, K, k, L, l, M, m, Nle, nle, P, p, R, r, S, s, Sem, T, t, V, v, W and w;
wherein X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W;
wherein X2014 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, R, S, T, V and W;
wherein X2015 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, Nle, R, S, T, V and W;
wherein X2016 is an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, Sem, T, V, W and Y;
wherein X2017 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y;
wherein X2018 is an amino acid selected from the group consisting of C and D, preferably C;
wherein X2019 is an amino acid selected from the group consisting of A, F, I, L, S, T, V and W;
wherein X2020 is an amino acid selected from the group consisting of F and W;
wherein X2021 is an amino acid selected from the group consisting of I, L and V;
wherein X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, and W;
wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y; and
wherein the peptide comprises as a cyclic structure generated by a linkage between X2007 and X2018.

### Claim 34

(canceled)

### Claim 35 (depends on 33)

The peptide according to claim 33,
wherein X2001 is either present or absent, whereby in case X2001 is present it is an amino acid selected from the group consisting of A, D, F, G, H, K, L, P and S;
wherein X2002 is an amino acid selected from the group consisting of A, F, H, K, L, M, R and S;
wherein X2003 is an amino acid selected from the group consisting of F, S and Y;
wherein X2004 is K;
wherein X2005 is W;
wherein X2006 is an amino acid selected from the group consisting of F, H, K and L;
wherein X2007 is C;
wherein X2008 is an amino acid selected from the group consisting of A, G and S;
wherein X2009 is an amino acid selected from the group consisting of M, Nle, p, Sem and V;
wherein X2010 is an amino acid selected from the group consisting of A, K, L, P, R and S;
wherein X2011 is an amino acid selected from the group consisting of D and S;
wherein X2012 is an amino acid selected from the group consisting of D, d, F, f, G, K, k, L, l, M, Nle, P, Sem and S;
wherein X2013 is an amino acid selected from the group consisting of A, D, F, G, K, L and S;
wherein X2014 is an amino acid selected from the group consisting of D and G;
wherein X2015 is an amino acid selected from the group consisting of I and T;
wherein X2016 is an amino acid selected from the group consisting of D, F, K, L, M, Nle, S, Sem and Y;
wherein X2017 is an amino acid selected from the group consisting of S and T;
wherein X2018 is C;
wherein X2019 is an amino acid selected from the group consisting of A, F, L, S and V;
wherein X2020 is W;
wherein X2021 is an amino acid selected from the group consisting of L and V;
wherein X2022 is an amino acid selected from the group consisting of A, F, G, K, L, P, R, S and W;
wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, F, G, L M, S and Y; and
wherein the peptide comprises a cyclic structure generated by a linkage between X2007 and X2018.

### Claim 36 (depends on 33)

The peptide according to claim 33,
wherein X2001 is an amino acid selected from the group consisting of A, D, F, G, H, K, L and S;
wherein X2002 is an amino acid selected from the group consisting of H, F, M and R;
wherein X2003 is an amino acid selected from the group consisting of F and Y;
wherein X2004 is K;
wherein X2005 is W;
wherein X2006 is an amino acid selected from the group consisting of F and H;
wherein X2007 is C;
wherein X2008 is an amino acid selected from the group consisting of A, G and S;
wherein X2009 is an amino acid selected from the group consisting of M, Sem and V;
wherein X2010 is an amino acid selected from the group consisting of K, P and R;
wherein X2011 is D;
wherein X2012 is an amino acid selected from the group consisting of F, L, l, M and Sem;
wherein X2013 is an amino acid selected from the group consisting of D, G, K and S;
wherein X2014 is G;
wherein X2015 is an amino acid selected from the group consisting of I and T;
wherein X2016 is an amino acid selected from the group consisting of D, F, M, Sem and Y;
wherein X2017 is an amino acid selected from the group consisting of S and T;
wherein X2018 is C;
wherein X2019 is an amino acid selected from the group consisting of A and V;
wherein X2020 is W;
wherein X2021 is V;
wherein X2022 is an amino acid selected from the group consisting of F, L, K, R, P and W;
wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid sequence selected from the group consisting of A, D, F, M, S and Y; and
wherein the peptide comprises as a cyclic structure generated by a linkage between X2017 and X2018.

### Claim at position 6

-40. (canceled)

### Claim 41

A peptide that binds TFPI, comprising the following structure of formula (VI):
X2001-X2002-F/Y-K-W-F/H-[C-X2008-MN-X2010-D-X2012-X2013-G-I/T-X2016-SIT-C]-A/V-W-V-X2022-X2023 (VI) (SEQ ID NO: 3119)
wherein X2001, X2002 and X2023 are each independently present or absent, wherein, if any of X2001, X2002 and X2023 is present, any of X2001, X2002 and X2023 is independently selected from any amino acid; and
wherein X2008, X2010, X2012, X2013, X2016 and X2022 are each independently selected from any amino acid.

### Claim 42

(canceled)

### Claim 43 (depends on 41)

The peptide according to claim 41, wherein
X2001 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W;
X2002 is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W;
X2008 is an amino acid selected from the group consisting of A, G, R, S and T;
X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P, R, S, T and V;
X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, I, K, k, L, l, M, m, Nle, nle, P, p, R, r, S, s, Sem, T, t, V, v, W and w;
X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W;
X2016 is an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, Sem, T, V, W and Y;
X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, and W; and
X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, M, S, T, V, W and Y.

### Claim 44 (depends on 43)

The peptide according to claim 43, wherein
X2001 is an amino acid selected from the group consisting of A, D, F, G, H, K, L and S;
X2002 is an amino acid selected from the group consisting of A, F, H, K, L, M, R and S;
X2008 is an amino acid selected from the group consisting of A, G and S;
X2010 is an amino acid selected from the group consisting of A, K, L, P, R and S;
X2012 is an amino acid selected from the group consisting of D, d, F, f, G, K, k, L, l, M, Nle, P, Sem and S;
X2013 is an amino acid selected from the group consisting of A, D, F, G, K, L and S;
X2016 is an amino acid selected from the group consisting of D, F, K, L, M, Nle, Sem and S;
X2022 is an amino acid selected from the group consisting of A, F, G, K, L, P, R, S and W; and
X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, F, G, L M, S and Y.

### Claim at position 11

-51. (canceled)

### Claim 52

A peptide that binds TFPI comprising an amino acid sequence of at least 60% identity to the sequence of formula VII:
(SEQ ID NO: 1040)
Ac-FYYKWH[CGMRDMKGTMSC]AWVKF-NH2 (VII)

### Claim 53 (depends on 52)

The peptide according to claim 52, wherein the amino acid sequence identity is at least 80%.

### Claim 54

(canceled)

### Claim 55

A peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1001-1210 and 1213-1293.

### Claim 56

A peptide that binds TFPI, comprising the following structure of formula (VIII):
X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-X3012-X3013-X3014-X3015-X3016-X3017-X3018-X3019-X3020-X3021 (VIII) (SEQ ID NO: 3120):
wherein X3001 is either present or absent, whereby in case X3001 is present it is an amino acid selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y;
wherein X3002 is either present or absent, whereby in case X3002 is present it is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, I and L;
wherein X3003 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P; Q, R, S, T, W and Y;
wherein X3004 is an amino acid selected from the group consisting of A, D, E, F, G, H, L, M, N, Q, R, S, T, V, W, Y and P;
wherein X3005 is an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R, S, T, V, W and Y;
wherein X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H;
wherein X3007 is an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S, T, W and Y;
wherein X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, Y and I;
wherein X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K;
wherein X3010 is an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;
wherein X3011 is an amino acid selected from the group consisting of A, G, I, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H;
wherein X3012 is an amino acid selected from the group consisting of A, C, H, I, K, L and R;
wherein X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I;
wherein X3014 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, N, Q, R, S, T, V, W, Y and K;
wherein X3015 is an amino acid selected from the group consisting of A, K and R;
wherein X3016 is an amino acid selected from the group consisting of A, F, K and R;
wherein X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, Y, H, A and M;
wherein X3018 is an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y;
wherein X3019 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V, W, Y and I;
wherein X3020 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, V, W, Y, I and P; and
wherein X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, P, Q, R, T, V, W, Y, F and G.

### Claim 57

(canceled)

### Claim 58 (depends on 56)

The peptide according to claim 56,
wherein X3001 is an amino acid selected from the group consisting of A, C, D, G, K, L, M, N, P, R, S, T, E, H and Y;
wherein X3002 is an amino acid selected from the group consisting of C, K, R, W, Y, G, I and L;
wherein X3003 is an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, R, S, T and W;
wherein X3004 is an amino acid selected from the group consisting of A, C, G, H, I, K, L, M, N, R, S, T and P;
wherein X3005 is an amino acid selected from the group consisting of C, F, H, K, R and W;
wherein X3006 is an amino acid selected from the group consisting of A, P and H;
wherein X3007 is an amino acid selected from the group consisting of L, C, R and W;
wherein X3008 is an amino acid selected from the group consisting of A, C, F, H, K, R, V, W, Y and I;
wherein X3009 is an amino acid selected from the group consisting of C, R, V and K;
wherein X3010 is an amino acid selected from the group consisting of A, C, K, L, Q, R and S;
wherein X3011 is an amino acid selected from the group consisting of I, K, L, M, R, V, W, C, F and H;
wherein X3012 is H;
wherein X3013 is an amino acid selected from the group consisting of C, K, R, V and I;
wherein X3014 is an amino acid selected from the group consisting of A, S, C, F, H, I, R and K;
wherein X3015 is an amino acid selected from the group consisting of K and R;
wherein X3016 is R;
wherein X3017 is an amino acid selected from the group consisting of C, G, I, K, L, N, Q, R, S, T, V, H, A and M;
wherein X3018 is an amino acid selected from the group consisting of K, C, I, R and W;
wherein X3019 is an amino acid selected from the group consisting of C, E, H, K, R and I;
wherein X3020 is an amino acid selected from the group consisting of C, M, I and P;
wherein X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, Q, R, V, W, F and G.

### Claim at position 19

-62. (canceled)

### Claim 63

A peptide that binds TFPI, comprising the following structure of formula (IX):
X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-H—X3013-X3014-K/R—R—X3017-X3018-X3019-X3020-X3021 (IX) (SEQ ID NO: 3121)
wherein X3001 and X3002 are independently either present or absent, wherein, if X3001 and/or X3002 are present, X3001 and/or X3002 are independently selected from any amino acid, and
wherein X3003, X3004, X3005, X3006, X3007, X3008, X3009, X3010, X3011, X3013, X3014, X3017, X3018, X3019, X3020 and X3021 are each independently selected from any amino acid.

### Claim at position 21

-82. (canceled)

### Claim 83

A peptide that binds TFPI, comprising an amino acid sequence of at least 60% identity to the sequence of formula (X):
(SEQ ID NO: 223)
Ac-GYASFPWFVQLHVHKRSWEMA-NH2 (X).

### Claim at position 23

-85. (canceled)

### Claim 86

A peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2001-2126, 2128-2296, and 2298-2498.

### Claim 87

A peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 3001-3048, 3051-3053, 3055, 3057-3064, and 3066-3108.

### Claim at position 26

-89. (canceled)

### Claim 90 (depends on 33)

The peptide according to claim 33, wherein the peptide is conjugated to a polyethylene glycol (PEG) moiety.

### Claim at position 28

-94. (canceled)

### Claim 95

A method for treating a blood coagulation disorder in a subject, the method comprising administering to the subject a peptide that inhibits TFPI activity, wherein the peptide is administered in an amount sufficient to treat the blood coagulation disorder in the subject.

### Claim 96

(canceled)

### Claim 97 (depends on 95)

The method according to a claim 95, wherein the peptide comprises the following structure of formula V:
X2001-X2002-X2003-X2004-005-X2006-[X2007-X2008-X2009-X2010-X2011-X2012-X2013-X2014-X2015-X2016-X2017-X2018]-X2019-X2020-X2021-X2022-X2023 (V) (SEQ ID NO: 3118)
wherein X2001 is either present or absent, whereby in case X2001 is present it is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W;
wherein X2002 is either present or absent, whereby in case X2002 is present it is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W;
wherein X2003 is an amino acid selected from the group consisting of A, F, I, K, L, R, S, T, V, W and Y;
wherein X2004 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V and W;
wherein X2005 is W;
wherein X2006 is an amino acid selected from the group consisting of F, H, I, K, L, R, V and W;
wherein X2007 is an amino acid selected from the group consisting of C, Hcy, Dap and K, preferably selected from the group consisting of C and Hcy;
wherein X2008 is an amino acid selected from the group consisting of A, G, R, S and T;
wherein X2009 is an amino acid selected from the group consisting of a, A, I, K, L, M, m, Nle, p, R, Sem and V;
wherein X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P, R, S,
Tandy;
wherein X2011 is an amino acid selected from the group consisting of D, E, G, S, and T;
wherein X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, K, k, L, l, M, m, Nle, nle, P, p, R, r, S, s, Sem, T, t, V, v, W and w;
wherein X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W;
wherein X2014 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, R, S, T, V and W;
wherein X2015 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, Nle, R, S, T, V and W.
wherein X2016 is an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, Sem, T, V, W and Y;
wherein X2017 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y.
wherein X2018 is an amino acid selected from the group consisting of C and D, preferably C;
wherein X2019 is an amino acid selected from the group consisting of A, F, I, L, S, T, V and W;
wherein X2020 is an amino acid selected from the group consisting of F and W;
wherein X2021 is an amino acid selected from the group consisting of I, L and V;
wherein X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, and W;
wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y; and
wherein the peptide comprises as a cyclic structure generated by a linkage between X2007 and X2018.

### Claim at position 32

-105. (canceled)

### Claim 106 (depends on 33)

A pharmaceutical compositing comprising a peptide as defined claim 33 and a pharmaceutical acceptable carrier.

### Claim at position 34

-133. (canceled)

### Claim 134 (depends on 41, 95)

The method according to claim 95, wherein the peptide is a peptide as defined in claim 41.
